The Neurology of AIDS

List of contents

Overview: a panel discussion, critical topics in the neurology of AIDS; SECTION 1: HIV-1 BIOLOGY, IMMUNOLOGY AND NEUROVIRULENCE; 1.1 The molecular biology of HIV-1; 1.2 Immunology of HIV-1; 1.3 HIV-1 structural and regulatory proteins and neurotoxicity; 1.4 The genetics of HIV-1 neuropathogenesis; SECTION 2: INNATE AND ACQUIRED IMMUNITY IN HIV-1 DEMENTIA; 2.1 Mononuclear phagocyte heterogeneity and the blood-brain barrier: A model for HIV-1 neuropathogenesis; 2.2 Common immune pathways of neural injury in neurodegenerative disorders; 2.3 HIV-1 vaccines; SECTION 3: THE BLOOD-BRAIN BARRIER AND HIV-1; 3.1 The blood-brain barrier, its structure and function; 3.2 The blood-brain barrier as an immunocompetent organ; 3.3 Viral receptors and the mechanisms of HIV-1 entry into cells and the central nervous system; 3.4 Mechanisms of viral entry through the blood-brain barrier; 3.5 The blood-brain barrier: monocyte and viral entry into the brain; 3.6 The choroid plexus and viral entry into the brain; SECTION 4: MECHANISMS OF NEUROTOXICITY BY HIV-1 AND CELLULAR IMMUNE PRODUCTS; 4.1 Mechanisms of macrophage-mediated neurotoxicity; 4.2 Chemokines, HIV-1 and the central nervous system; 4.3 Mechanisms of neuronal demise in HIV dementia: role of HIV-1 tat; 4.4 Protection against HIV-1gp120 and HIV-1 tat neurotoxicity; 4.5 Astrocyte immunobiology; 4.6 Transcriptional analysis of inflammatory and glial responses in the central nervous system: development of RNA fingerprints for neuroAIDS and other central nervous system disorders; 4.7 Neurogenesis and its links to brain development, developmental therapeutics, and the pathogenesis of neurodegenerative disorders including HIV-1-associated dementia; SECTION 5: ANIMAL MODEL SYSTEMS; 5.1 The simian immunodeficiency virus/macaque model: detailing viral weapons and host defenses in HIV central nervous system disease; 5.2 The feline immunodeficiency virus model of HIV-1 associated neurologic disease; 5.3 Neurologic disease produced by maedi-visna and caprine arthritis-encephalitis viruses, lentiviruses of sheep and goats; 5.4 Murine model systems for studies of HIV-1 associated dementia; 5.5 Studies of adaptive immunity in a murine model of HIV-1 encephalitis; 5.6 Laboratory model systems of drug abuse and their relevance to HIV infection and dementia; SECTION 6: LIVING WITH HIV AND AIDS (CLINICAL PERSPECTIVES FROM PATIENTS LIVING WITH THE NEUROLOGICAL CONSEQUENCES OF HIV INFECTION); 6.1 HIV dementia: living with the suffering, the diagnosis and the uncertainties; 6.2 Neurological manifestations of HIV disease; 6.3 Coping with depression; 6.4 Living with families with HIV in an African community: a mental health point of view; 6.5 HIV and sexual dysfunction: a patient's view; SECTION 7: CLINICAL AND PATHOLOGICAL ASPECTS OF DISEASE; 7.1 An overview of the clinical and biologic features of the AIDS dementia complex; 7.2 HIV Neurocognitive disorders; 7.3 The neuropathology of HIV-associated brain disease; 7.4 Brain pathology in HIV-1 infected drug abusers; 7.5 Current concepts in HIV neuropathogenesis: neuronal injury, white matter disease and neurotrophic factors; 7.6 Spinal cord disease: clinical presentations and pathology; 7.7 The spectrum of peripheral neuropathies in AIDS; 7.8 The neuropathology of HIV-related neuropathies; 7.9 Myopathies associated with HIV-1: clinical and pathological manifestations; 7.10 Human polyomavirus, JCV and progressive multifocal leukoencephalopathy; 7.11 Central nervous system neoplasms in AIDS; 7.12 Opportunistic infections of the nervous system in AIDS; 7.13 Hepatitis C; 7.14 Alcohol and HIV-1 neuropathogenesis; 7.15 Psychiatric disorders; SECTION 8: DIAGNOSTIC METHODS FOR MONITORING COGNITIVE FUNCTION IN NEUROAIDS; 8.1 Structural brain imaging; 8.2 Magnetic resonance spectroscopy of animal models of neuroAIDS; 8.3 Magnetic resonance spectroscopy and functional magnetic resonance imaging in the evaluation of HIV-associated brain injury; 8.4 Evoked potentials; 8.5 Neuropsychology of HIV; 8.6 The effects of antiretroviral therapy on viral and non-viral markers in cerebrospinal fluid; 8.7 Compartmentalization of HIV infection in the central nervous system; SECTION 9: HIV-1 ENCEPHALOPATHY: UNIQUE ASPECTS IN CHILDREN AND ADOLESCENTS; 9.1 Clinical features; 9.2 Neuropathologic aspects of HIV-1 infection in children; 9.3 Evaluation of neurodevelopmental deficits in children with HIV-1 infection; 9.4 Psychosocial aspects of neurologic impairment in children with AIDS; 9.5 Antiretroviral therapy in children; SECTION 10: ANTIRETROVIRAL AND ADJUNCTIVE DRUG STRATEGIES FOR NEUROAIDS AND TREATMENT FOR OPPORTUNISTIC INFECTIONS; 10.1 Current concepts in the treatment of HIV infection with focus on brain disease; 10.2 Treatment of opportunistic infections associated with HIV infection; 10.3 Pharmacology of antiretroviral drug in the central nervous system: pharmacokinetics, antiretroviral resistance, and pharmacodynamics; 10.4 Development of adjunctive therapies for the neurological manifestations of AIDS: Dementia and painful neuropathy; SECTION 11: SOCIAL AND BEHAVIOURAL CONSEQUENCES OF HIV-INFECTION; 11.1 Everyday impact of HIV-associated neurocognitive disorders; 11.2 Coping, methamphetamine, and HIV-1; 11.3 Club drugs and HIV transmission; 11.4 Facing legal and ethical challenges in the treatment of AIDS; 11.5 AIDS-related death anxiety: A research review and clinical recommendations; 11.6 Clinical-neuropathological correlation in HIV in the era of highly active antiretroviral therapy; 11.7 Pain management in HIV infection

Product details

• Authors: Howard E. Gendelman
• Assisted by: Ian P. Everall (Editor), Howard Gendelman (Editor), Howard E. Gendelman (Editor), Igor Grant (Editor)
• Publisher: Oxford University Press
• Languages: English
• Product format: Hardback
• Released: 12.05.2005
• EAN: 9780198526100
• ISBN: 978-0-19-852610-0
• No. of pages: 829
• Dimensions: 222 mm x 292 mm x 38 mm
• Subject: Natural sciences, medicine, IT, technology > Medicine